Cargando…
Human Plasma Xanthine Oxidoreductase Activity in Cardiovascular Disease: Evidence from a Population-Based Study
Xanthine oxidoreductase (XOR) and its products contribute to the development of chronic inflammation and oxidative stress. Excessive XOR activity is believed to promote inflammatory responses and atherosclerotic plaque formation, which are major cardiovascular risk factors. The mechanisms of XOR act...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045414/ https://www.ncbi.nlm.nih.gov/pubmed/36979733 http://dx.doi.org/10.3390/biomedicines11030754 |
_version_ | 1784913597911007232 |
---|---|
author | Kotozaki, Yuka Satoh, Mamoru Nasu, Takahito Tanno, Kozo Tanaka, Fumitaka Sasaki, Makoto |
author_facet | Kotozaki, Yuka Satoh, Mamoru Nasu, Takahito Tanno, Kozo Tanaka, Fumitaka Sasaki, Makoto |
author_sort | Kotozaki, Yuka |
collection | PubMed |
description | Xanthine oxidoreductase (XOR) and its products contribute to the development of chronic inflammation and oxidative stress. Excessive XOR activity is believed to promote inflammatory responses and atherosclerotic plaque formation, which are major cardiovascular risk factors. The mechanisms of XOR activity in the development and progression of cardiovascular disease (CVD), coupled with the complexity of the relationship between XOR activity and the biological effects of uric acid; reactive oxygen species; and nitric oxide, which are the major products of XOR activity, have long been debated, but have not yet been clearly elucidated. Recently, a system for measuring highly sensitive XOR activity in human plasma was established, and there has been progress in the research on the mechanisms of XOR activity. In addition, there are accumulating findings about the relationship between XOR activity and CVD. In this narrative review, we summarize existing knowledge regarding plasma XOR activity and its relationship with CVD and discuss future perspectives. |
format | Online Article Text |
id | pubmed-10045414 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100454142023-03-29 Human Plasma Xanthine Oxidoreductase Activity in Cardiovascular Disease: Evidence from a Population-Based Study Kotozaki, Yuka Satoh, Mamoru Nasu, Takahito Tanno, Kozo Tanaka, Fumitaka Sasaki, Makoto Biomedicines Review Xanthine oxidoreductase (XOR) and its products contribute to the development of chronic inflammation and oxidative stress. Excessive XOR activity is believed to promote inflammatory responses and atherosclerotic plaque formation, which are major cardiovascular risk factors. The mechanisms of XOR activity in the development and progression of cardiovascular disease (CVD), coupled with the complexity of the relationship between XOR activity and the biological effects of uric acid; reactive oxygen species; and nitric oxide, which are the major products of XOR activity, have long been debated, but have not yet been clearly elucidated. Recently, a system for measuring highly sensitive XOR activity in human plasma was established, and there has been progress in the research on the mechanisms of XOR activity. In addition, there are accumulating findings about the relationship between XOR activity and CVD. In this narrative review, we summarize existing knowledge regarding plasma XOR activity and its relationship with CVD and discuss future perspectives. MDPI 2023-03-01 /pmc/articles/PMC10045414/ /pubmed/36979733 http://dx.doi.org/10.3390/biomedicines11030754 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Kotozaki, Yuka Satoh, Mamoru Nasu, Takahito Tanno, Kozo Tanaka, Fumitaka Sasaki, Makoto Human Plasma Xanthine Oxidoreductase Activity in Cardiovascular Disease: Evidence from a Population-Based Study |
title | Human Plasma Xanthine Oxidoreductase Activity in Cardiovascular Disease: Evidence from a Population-Based Study |
title_full | Human Plasma Xanthine Oxidoreductase Activity in Cardiovascular Disease: Evidence from a Population-Based Study |
title_fullStr | Human Plasma Xanthine Oxidoreductase Activity in Cardiovascular Disease: Evidence from a Population-Based Study |
title_full_unstemmed | Human Plasma Xanthine Oxidoreductase Activity in Cardiovascular Disease: Evidence from a Population-Based Study |
title_short | Human Plasma Xanthine Oxidoreductase Activity in Cardiovascular Disease: Evidence from a Population-Based Study |
title_sort | human plasma xanthine oxidoreductase activity in cardiovascular disease: evidence from a population-based study |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045414/ https://www.ncbi.nlm.nih.gov/pubmed/36979733 http://dx.doi.org/10.3390/biomedicines11030754 |
work_keys_str_mv | AT kotozakiyuka humanplasmaxanthineoxidoreductaseactivityincardiovasculardiseaseevidencefromapopulationbasedstudy AT satohmamoru humanplasmaxanthineoxidoreductaseactivityincardiovasculardiseaseevidencefromapopulationbasedstudy AT nasutakahito humanplasmaxanthineoxidoreductaseactivityincardiovasculardiseaseevidencefromapopulationbasedstudy AT tannokozo humanplasmaxanthineoxidoreductaseactivityincardiovasculardiseaseevidencefromapopulationbasedstudy AT tanakafumitaka humanplasmaxanthineoxidoreductaseactivityincardiovasculardiseaseevidencefromapopulationbasedstudy AT sasakimakoto humanplasmaxanthineoxidoreductaseactivityincardiovasculardiseaseevidencefromapopulationbasedstudy |